Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001469709-16-000821
Filing Date
2016-05-17
Accepted
2016-05-17 14:24:04
Documents
54
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 ENDV 10-K/A 12/31/15 endv10ka_123115apg.htm 10-K/A 603800
2 GRAPHIC endv10ka_123115apg001.jpg GRAPHIC 41005
3 EXHIBIT 31.1 ex31_1apg.htm EX-31.1 7500
4 EXHIBIT 32.1 ex32_1apg.htm EX-32.1 3187
  Complete submission text file 0001469709-16-000821.txt   3051175

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE endv-20151231.xml EX-101.INS 515469
6 XBRL SCHEMA FILE endv-20151231.xsd EX-101.SCH 42369
7 XBRL CALCULATION FILE endv-20151231_cal.xml EX-101.CAL 41396
8 XBRL DEFINITION FILE endv-20151231_def.xml EX-101.DEF 63254
9 XBRL LABEL FILE endv-20151231_lab.xml EX-101.LAB 211593
10 XBRL PRESENTATION FILE endv-20151231_pre.xml EX-101.PRE 181584
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

EIN.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-55453 | Film No.: 161657032
SIC: 2834 Pharmaceutical Preparations